Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced the dosing ...
News FM Lee Ik-seon Choi Soo-young Issue & People] □ Broadcast date and time: November 1, 2024 (Fri)□ Host: Lee Ik-seon, Choi Soo-young□ Cast: Choi ...
Researchers conducted a study to determine if variations in the MTNR1A gene, specifically the MRNR1A variant (rs374152717), could be a genetic cause of idiopathic osteoporosis.
"Angitia doses first subject in Phase II trial of AGA2118 for treating osteoporosis" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
Researchers employed analysis tools and machine learning algorithms to identify two genes linked to rheumatoid arthritis and osteoporosis that could serve as diagnostic tools and potential targets for ...
JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today reported ...
Panelists discuss how to effectively integrate vasomotor symptom (VMS) treatment into comprehensive health management plans for women, taking into account the significant comorbidities associated with ...